

SUDA Pharmaceuticals Ltd

10:39 22 Sep 2020

SUDA Pharmaceuticals anagrelide oral spray formulation supported by new study results

SUDA Pharmaceuticals Ltd (ASX:SUD) (FRA:E4N) has welcomed study results that support the company's hypothesis that an anagrelide oral spray formulation may offer a safer alternative to the current commercial capsule to treat metastatic disease in patients with certain solid tumour cancers.

A final report was recently received for a canine pharmacokinetic study completed at Covance Inc, Harrogate, UK, where three carefully selected experimental oral spray formulations of anagrelide were compared with the commercial capsule form of the drug, Xagrid.

The objective of the study was to compare plasma levels of anagrelide and its cardiostimulatory metabolite following administration of the oral spray formulations with those after dosing with the capsule.

Increase in bioavailability

One of the novel formulations, SS-101, resulted in a statistically significant increase in bioavailability of the drug of 43%, suggesting buccal absorption through the cheek and showed an increase of only 28% in exposure to the cardiostimulatory metabolite relative to the capsule formulation.

According to Covance, this provides evidence that a proportion of the drug from formulation SS-101 reaches the bloodstream by crossing the lining of the cheek and suggests that a lower dose of anagrelide could be administered to cancer patients.

"Exciting development"

Project director Dr Richard Franklin said: "This is a very exciting development for the project.

"While we were hoping that all three of the oral spray formulations tested would have superior properties to the capsule form of the drug, we are delighted that one formulation, in particular, showed evidence of buccal absorption, increased bioavailability and reduced exposure to the cardiostimulatory metabolite."

The other two formulations, EF-164 and EF-169, displayed a 27% increase and an 8% decrease in bioavailability over the capsule, respectively.

Price: 0.04

Market Cap: \$12.27 m

1 Year Share Price Graph



Share Information

Code: SUD

Listing: ASX

52 week High Low
0.097 0.0245694


Sector: Medical technology & services

Website: www.sudapharma.com

Company Synopsis:

SUDA Pharmaceuticals Ltd (ASX:SUD) is a drug delivery company focused on oromucosal administration. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals.

action@proactiveinvestors.com.au



Formulation SS-101 displayed a statistically significant increase in bioavailability over the capsule of 43%.

Treatment of metastatic disease

SUDA is developing anagrelide for the treatment of metastatic disease in patients who have certain solid tumour cancers.

Clinical experience has shown that increased platelet numbers associated with several solid tumour cancers decrease progression-free life expectancy.

Furthermore, anagrelide not only advantageously lowers blood platelets but it has also been shown to inhibit cancer cell movement towards platelet-producing cells, megakaryocytes, principally found in the bone marrow but also the lung, two likely sites of metastases.

Anagrelide has already been approved for the treatment of Essential Thrombocythemia (ET), in which patients have elevated platelet numbers and are at risk of thrombosis.

Oral spray benefits

A limiting factor for the widespread use of anagrelide in cancer in its current capsule form is the production of a cardiostimulatory metabolite that is generated during first-pass metabolism of the drug in the liver.

SUDA has shown that using one of its novel oral spray formulations, a proportion of the drug reaches the bloodstream by crossing the buccal membrane in the mouth, enabling increased levels of the drug to reach the bloodstream directly, while reducing the relative exposure to the cardiostimulatory metabolite that is generated.

This supports SUDA's hypothesis that such a novel formulation of anagrelide may serve as a safer way to treat metastatic disease in cancer patients.

Next steps

SUDA will continue to optimise formulation SS-101 to ensure its stability and to produce a pharmaceutical-grade product.

Once the final formulation has been established, SUDA intends to complete the required pre-clinical toxicology studies prior to initiating clinical trials.

As the drug itself has previously been approved by both the FDA and the EMA for ET, it is anticipated that a reduced package of preclinical testing will be required for the development of an oral spray version of anagrelide.

As of June 30, 2020, and taking into account a recent capital raising, SUDA had a solid cash position of \$4.9 million which will be used to develop anagrelide.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).